Last 7 days
-3.6%
Last 30 days
-5.1%
Last 90 days
-7.5%
Trailing 12 Months
32.8%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 396.9B | 94.9B | -4.42% | -11.67% | 22.12 | 4.18 | 1.25% | -14.07% |
LLY | 298.8B | 28.5B | 1.30% | 17.85% | 47.85 | 10.47 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -5.09% | 32.83% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.2B | 100.3B | -5.50% | -20.78% | 7.21 | 2.25 | 23.43% | 42.74% |
BMY | 142.4B | 46.2B | -5.97% | -4.10% | 22.5 | 3.08 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.5B | 4.5B | -8.55% | -11.11% | -32.05 | 1.01 | 7.56% | -104.06% |
RETA | 3.2B | 2.2M | 109.33% | 133.59% | -10.15 | 1.4K | -80.71% | -4.88% |
SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -10.48% | 10.28% | 30.48 | 2.77 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -5.76% | -54.20% | -2.78 | 2.67 | 18.18% | -18.59% |
CGC | 923.6M | 478.9M | -20.83% | -73.20% | -0.29 | 1.93 | -31.50% | -634.70% |
INVA | 772.8M | 285.2M | -9.04% | -42.36% | 3.51 | 2.71 | -27.21% | -40.28% |
CRON | 726.9M | 114.5M | -12.79% | -47.96% | -4.31 | 6.35 | 27.90% | 57.40% |
ACRS | 539.5M | 29.8M | -36.94% | -53.16% | -6.21 | 18.13 | 340.05% | 4.35% |
OCUL | 379.1M | 51.5M | -14.46% | -5.94% | -5.34 | 7.36 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 0.5% | 59,283 | 58,974 | 57,169 | 53,978 | 48,704 |
S&GA Expenses | -1.4% | 10,042 | 10,185 | 10,001 | 9,770 | 9,634 |
R&D Expenses | 5.5% | 13,548 | 12,841 | 10,887 | 12,410 | 12,245 |
EBITDA | -2.1% | 18,268 | 18,664 | 21,157 | 18,246 | - |
EBITDA Margin | -2.6% | 0.31* | 0.32* | 0.37* | 0.34* | - |
Earnings Before Taxes | -2.4% | 16,444 | 16,840 | 18,523 | 15,753 | 13,879 |
EBT Margin | -2.9% | 0.28* | 0.29* | 0.32* | 0.29* | - |
Interest Expenses | 4.5% | 888 | 850 | 806 | - | - |
Net Income | -4.9% | 14,519 | 15,260 | 16,579 | 14,180 | 13,049 |
Net Income Margin | -5.4% | 0.24* | 0.26* | 0.29* | 0.26* | - |
Free Cahsflow | -3.4% | 19,095 | 19,760 | 18,955 | 16,092 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 1.9% | 109,160 | 107,081 | 107,095 | 106,668 | 105,694 |
Current Assets | 6.4% | 35,722 | 33,561 | 32,116 | 31,184 | 30,266 |
Cash Equivalents | 13.9% | 12,694 | 11,145 | 9,675 | 8,556 | 8,096 |
Inventory | 5.3% | 5,911 | 5,614 | 5,535 | 5,774 | 5,953 |
Net PPE | 4.9% | 21,422 | 20,424 | 20,059 | 19,747 | 19,279 |
Goodwill | 0.2% | 21,204 | 21,160 | 21,213 | 21,258 | 21,264 |
Current Liabilities | 5.4% | 24,239 | 22,998 | 23,168 | 22,316 | 23,872 |
LT Debt, Current | - | 2,300 | - | - | - | - |
LT Debt, Non Current | 0.9% | 28,745 | 28,482 | 28,684 | 30,586 | 30,690 |
Shareholder's Equity | 3.4% | 45,991 | 44,458 | 43,318 | 40,953 | 38,184 |
Retained Earnings | 1.9% | 61,081 | 59,928 | 58,437 | 56,252 | 53,696 |
Additional Paid-In Capital | 0.3% | 44,379 | 44,243 | 44,115 | 44,275 | 44,238 |
Accumulated Depreciation | 0.4% | 17,985 | 17,921 | 17,798 | 18,498 | 18,192 |
Minority Interest | 1.5% | 67.00 | 66.00 | 75.00 | 70.00 | 73.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -3.4% | 19,095 | 19,760 | 18,955 | 16,643 | 13,122 |
Share Based Compensation | 5.0% | 541 | 515 | 493 | 488 | 479 |
Cashflow From Investing | 67.5% | -4,960 | -15,261 | -15,360 | -16,908 | -16,421 |
Cashflow From Financing | -286.7% | -9,119 | -2,358 | -1,930 | 2,109 | 3,097 |
Dividend Payments | 1.5% | 7,012 | 6,905 | 6,807 | 6,710 | 6,610 |
Buy Backs | -100.0% | 0.00 | 36.00 | 1,202 | 840 | - |
16.5%
0%
0%
Y-axis is the maximum loss one would have experienced if Merck was unfortunately bought at previous high price.
12.9%
14.1%
18.6%
21.3%
FIve years rolling returns for Merck.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 0.12 | 4,918,200 | 21,436,200 | 0.60% |
2023-03-13 | Claro Advisors LLC | added | 30.13 | 439,275 | 1,192,280 | 0.39% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -2.09 | 89,259,000 | 430,663,000 | 0.47% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 3,421 | 16,421 | -% |
2023-03-10 | MATHER GROUP, LLC. | added | 3.46 | 765,244 | 3,065,240 | 0.06% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -0.43 | 586,661 | 2,660,660 | 0.42% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 1.33 | 593,991 | 2,345,990 | 0.19% |
2023-03-07 | Great Lakes Retirement, Inc. | new | - | 565,897 | 565,897 | 0.14% |
2023-03-06 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | reduced | -2.95 | 1,153,190 | 5,758,190 | 2.19% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | added | 14.45 | 458,334 | 1,423,330 | 0.09% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 8.96% | 227,205,978 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 8.5% | 215,011,385 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 8.36% | 211,202,531 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 7.8% | 198,224,264 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 8.24% | 208,410,644 | SC 13G/A | |
Feb 05, 2021 | blackrock inc. | 7.8% | 196,213,804 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 8.26% | 210,542,333 | SC 13G/A | |
Feb 05, 2020 | blackrock inc. | 7.5% | 190,783,225 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Feb 24, 2023 | 10-K | Annual Report | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 14, 2023 | 4 | Insider Trading | |
Feb 13, 2023 | 4 | Insider Trading | |
Feb 10, 2023 | 4 | Insider Trading | |
Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
Feb 08, 2023 | 4 | Insider Trading | |
Feb 06, 2023 | 4 | Insider Trading | |
Feb 03, 2023 | SC 13G/A | Major Ownership Report | |
Feb 02, 2023 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-02-15 | Romanelli Joseph | sold | -541,100 | 108 | -5,000 | president, human health int?l |
2023-02-13 | MIZELL STEVEN | sold | -198,017 | 109 | -1,815 | evp, chief hr officer |
2023-02-10 | Williams David Michael | acquired | 128,598 | 106 | 1,205 | evp,chief info&digital officer |
2023-02-10 | Williams David Michael | sold (taxes) | -44,075 | 106 | -413 | evp,chief info&digital officer |
2023-02-09 | MIZELL STEVEN | sold | -535,006 | 107 | -5,000 | evp, chief hr officer |
2023-02-06 | MIZELL STEVEN | sold | -462,473 | 104 | -4,436 | evp, chief hr officer |
2023-02-03 | Zachary Jennifer | sold | -7,782,760 | 103 | -75,436 | evp, general counsel |
2023-02-03 | Zachary Jennifer | acquired | 4,227,430 | 56.04 | 75,436 | evp, general counsel |
2023-01-23 | Davis Robert M | acquired | 2,661,730 | 109 | 24,224 | ceo & president |
2023-01-23 | Chattopadhyay Sanat | acquired | 1,922,350 | 109 | 17,495 | exe v-p & pres. mmd |
Consolidated Statement of Income - USD ($) $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Sales | $ 59,283 | $ 48,704 | $ 41,518 |
Costs, Expenses and Other | |||
Cost of sales | 17,411 | 13,626 | 13,618 |
Selling, general and administrative | 10,042 | 9,634 | 8,955 |
Research and development | 13,548 | 12,245 | 13,397 |
Restructuring costs | 337 | 661 | 575 |
Other (income) expense, net | 1,501 | (1,341) | (890) |
Total costs, expenses and other | 42,839 | 34,825 | 35,655 |
Income from Continuing Operations Before Taxes | 16,444 | 13,879 | 5,863 |
Taxes on Income from Continuing Operations | 1,918 | 1,521 | 1,340 |
Net Income from Continuing Operations | 14,526 | 12,358 | 4,523 |
Less: Net Income Attributable to Noncontrolling Interests | 7 | 13 | 4 |
Net Income from Continuing Operations Attributable to Merck & Co., Inc. | 14,519 | 12,345 | 4,519 |
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | 0 | 704 | 2,548 |
Net Income Attributable to Merck & Co., Inc. | $ 14,519 | $ 13,049 | $ 7,067 |
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | |||
Income from Continuing Operations (in dollars per share) | $ 5.73 | $ 4.88 | $ 1.79 |
Income from Discontinued Operations (in dollars per share) | 0 | 0.28 | 1.01 |
Net Income (in dollars per share) | 5.73 | 5.16 | 2.79 |
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | |||
Income from Continuing Operations (in dollars per share) | 5.71 | 4.86 | 1.78 |
Income from Discontinued Operations (in dollars per share) | 0 | 0.28 | 1.00 |
Net Income (in dollars per share) | $ 5.71 | $ 5.14 | $ 2.78 |
Consolidated Balance Sheet - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 12,694 | $ 8,096 |
Short-term investments | 498 | 0 |
Accounts receivable (net of allowance for doubtful accounts of $72 in 2022 and $62 in 2021) | 9,450 | 9,230 |
Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021 classified in Other assets - see Note 8) | 5,911 | 5,953 |
Other current assets | 7,169 | 6,987 |
Total current assets | 35,722 | 30,266 |
Investments | 1,015 | 370 |
Property, Plant and Equipment (at cost) | ||
Land | 295 | 326 |
Buildings | 13,166 | 12,529 |
Machinery, equipment and office furnishings | 16,760 | 16,303 |
Construction in progress | 9,186 | 8,313 |
Property, plant and equipment (at cost) | 39,407 | 37,471 |
Less: accumulated depreciation | 17,985 | 18,192 |
Property, plant and equipment, net | 21,422 | 19,279 |
Goodwill | 21,204 | 21,264 |
Other Intangibles, Net | 20,269 | 22,933 |
Other Assets | 9,528 | 11,582 |
Total Assets | 109,160 | 105,694 |
Current Liabilities | ||
Loans payable and current portion of long-term debt | 1,946 | 2,412 |
Trade accounts payable | 4,264 | 4,609 |
Accrued and other current liabilities | 14,159 | 13,859 |
Income taxes payable | 1,986 | 1,224 |
Dividends payable | 1,884 | 1,768 |
Total current liabilities | 24,239 | 23,872 |
Long-Term Debt | 28,745 | 30,690 |
Deferred Income Taxes | 1,795 | 3,441 |
Other Noncurrent Liabilities | 8,323 | 9,434 |
Merck & Co., Inc. Stockholders’ Equity | ||
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021 | 1,788 | 1,788 |
Other paid-in capital | 44,379 | 44,238 |
Retained earnings | 61,081 | 53,696 |
Accumulated other comprehensive loss | (4,768) | (4,429) |
Stockholders' equity before deduction for treasury stock | 102,480 | 95,293 |
Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021 | 56,489 | 57,109 |
Total Merck & Co., Inc. stockholders’ equity | 45,991 | 38,184 |
Noncontrolling Interests | 67 | 73 |
Total equity | 46,058 | 38,257 |
Total Liabilities and Equity | $ 109,160 | $ 105,694 |